

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BASF SE	04/30/2008
RECEIVING PARTY DATA	
Name:	Dr. Reddy's Laboratories Louisiana, LLC
Street Address:	200 Somerset Corporate Blvd., 7th Floor
City:	Bridgewater
State/Country:	NEW JERSEY
Postal Code:	08807-2862
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	6251945
Patent Number:	6726929
CORRESPONDENCE DATA	
Fax Number:	(908)203-6515
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	908-203-6504
Email:	patpros@drreddys.com
Correspondent Name:	Robert A. Franks
Address Line 1:	200 Somerset Corporate Blvd., 7th Floor
Address Line 4:	Bridgewater, NEW JERSEY 08807-2862
NAME OF SUBMITTER:	Robert A. Franks
Total Attachments: 4 source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif source=Assignment#page4.tif	

CH \$80.00 6251945

501092625

PATENT
REEL: 023928 FRAME: 0739

Patent Assignment Agreement

This Patent Assignment Agreement is made on the 30th day of April 2008 between
BASF SE, Carl-Bosch-Straße 38, 67056 Ludwigshafen/Rhein, Germany (the “**Assignor**”)
and Dr. Reddy’s Laboratories Louisiana, LLC, 200 Somerset Corporate Blvd., Seventh Floor,
Bridgewater, New Jersey 08807-2862, United States of America (the “**Assignee**”).

Preamble

- (A) WHEREAS, Assignor and Assignee concluded an agreement regarding certain patent rights relating to dosage forms of Profens;
- (B) WHEREAS, the Assignor, formerly BASF Aktiengesellschaft, is the registered owner of the patent and patent application (the “**Patents**”) listed in the Schedule attached hereto; and
- (C) WHEREAS, the Assignor has agreed to assign the Patents to the Assignee, and the Assignee has agreed to accept such assignment from the Assignor.

NOW THEREFORE,

1. The Assignor hereby assigns to the Assignee its full rights and title to the Patents listed in the Schedule of this Agreement and the Assignee hereby accepts such assignment from the Assignor.
2. Assignee hereby grants to Assignor an exclusive, royalty-free license to practice any invention that is claimed in U.S. Patent No. 6,251,945 and agrees to cooperate with Assignor, at the expense of Assignor, as is reasonably required to support Assignor’s efforts to enforce U.S. Patent No. 6,251,945 against any unlicensed infringing party.
3. The consideration for such assignment shall be USD 500.000 plus applicable VAT, if any.

4. The Assignor shall, at its own cost, provide to the Assignee any and all documents relating to the Assignor's right, title and interest to the Patents as the Assignor has at its disposition, and shall procure and execute additional documents as are necessary for recording the transfer of title to Assignee at a relevant patent office.
5. The Assignee shall, at its own costs, apply to record the transfer of title of the Patents from the currently registered proprietor to the Assignee at the relevant national patent offices.
6. The Assignor shall as soon as possible and in any event, within 60 (sixty) days of the date of this Agreement transfer to and provide to the Assignee, or at the Assignee's option its appointed patent attorney, all original data and documentation, correspondence, files and records in its possession and relating to the Patents.
7. All notices or other communications to Assignor required hereunder shall be in writing and shall be delivered to the following address.

BASF SE

Global Intellectual Property

Carl-Bosch-Strasse 38

67056 Ludwigshafen

Fax +49 -621 60 43123


8. The parties hereto shall keep the terms and conditions of this Agreement in strict confidence and shall not disclose the contents of this Agreement to any third party, except to the extent that disclosure is required under a lawful order of a court or government agency. Notwithstanding the forgoing, Assignee may use and disclose the terms and conditions of this Agreement to the extent necessary to exercise its rights under this Agreement, including without limitation recording this Agreement

with the relevant national patent offices provided that the monetary terms are redacted.

9. In the event, that Assignee intends to let any of the Patents and Applications become abandoned or allow any of the Patents expire prematurely, then Assignee shall notify the Assignor of such intent at least 90 days before the date upon which any such foregoing act or omission would cause the corresponding result. In the event that Assignor wishes to continue to maintain any of such Patents and Applications in force, Assignee agrees to transfer their ownership to Assignor without consideration therefor.
10. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives.
11. Assignor hereby warrants and represents that it has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
12. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any choice or conflict of law provision rule that would cause the application of the laws of any other jurisdiction other than Delaware.

Dr. Reddy's Laboratories Louisiana, LLC.

BASF SE

 Name: Ravi

Title: SUP - Finance

Name: Dr. Alexandra Brand i.V. Goldscheid
Dr. Alexandra Brand
Director Global Marketing Pharma Ingredients
Title: Senior Counsel

Schedule

Patents or Patent applications	Dates of filing and granting	Applicants/ Owners	Title
U.S. Patent No. 6,726,929	Filed June 14, 2001 and Granted April 27, 2004	BASF Aktiengesellschaft (Ludwigshafen, DE)	Pharmaceutical mixture comprising a profen
Canadian Patent Application Serial No. 2.355.291	Filed June 13, 2001	BASF Aktiengesellschaft (Ludwigshafen, DE)	A pharmaceutical mixture comprising a profen
U.S. Patent No. 6,251,945	Filed January 14, 1999 and Granted June 26, 2001	BASF Aktiengesellschaft (Ludwigshafen, DE)	Pharmaceutical mixture comprising a combination of a profen and other active compounds